DEVON, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated a Phase 2 clinical trial, STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis (OA)), of ZYN002 cannabidiol (CBD) gel. ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery.
“In the US, there are approximately 31 million people who suffer from osteoarthritis, many of whom are not receiving adequate relief from current therapies,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “In preclinical models, cannabidiol has demonstrated the ability to significantly reduce pain and inflammation associated with OA. ZYN002 may offer an effective treatment alternative